secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001703057-23-000020
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera Q2 revenue drops 78% to $10M; net loss widens to $0.11/share
----------------------------------------------------------------------

- Total revenue $10.1M vs $45.9M in Q2 2022; research fees fell to $9.8M from $12.5M.
- Net loss $30.5M ($0.11/sh) vs net loss $6.8M ($0.02/sh) in Q2 2022; R&D spending rose to $36.5M.
- Cash, equivalents and marketable securities $822.9M; secured $220M in strategic financing from Canadian govts.
- Cumulative partnered program starts up 20% YoY to 106; 9 molecules advanced to clinic vs 6 a year ago.
- Total programs under contract 177 with 41 partners, up from 164 and 38 a year ago.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000170305723000020/0001703057-23-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000170305723000020/abcl-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001703057-23-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer